Developer docs
API playgroundTry for free, no card

Search company profiles

Modern Synthesis

Full company profile

uuid0000u2p

Namestring
Modern Synthesis
Legal namestring
Modern Synthesis
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Modern Synthesis is a London-based biomaterials company founded in 2020 that develops and supplies bacterial nanocellulose (BNC) materials grown from the Komagataeibacter rhaeticus bacterium. The company operates a proprietary, patent-pending BNC platform supported by an academic collaboration with Imperial College, and layers a machine-learning-driven material optimization workflow over the wet-lab process to accelerate iteration on properties such as hand-feel, strength, and dye uptake. The commercial proposition targets B2B customers in fashion and, increasingly, automotive interiors, where the material is positioned as a lower-impact, drop-in alternative to leather and synthetic substrates.

The company sells biomaterial sheets and finished prototypes to brand partners on a project and licensing basis rather than through disclosed high-volume contracts. Early commercial showcases include the 2023 GANNI Bou Bag and a BEEN London tote demonstration piece, with a 2025 Korvaa Consortium shoe marking entry into footwear. Revenue conversion has lagged announced timelines, and the company has publicly acknowledged difficulty achieving commercial sales, indicating that to date activity sits in the pilot-to-early-commercial phase supported by a brand waitlist rather than recurring volume.

Modern Synthesis is venture-backed, having raised approximately $4.1M in a June 2022 seed round and $5.5M in a February 2025 seed extension led by Extantia Capital, alongside Innovate UK non-dilutive funding. The team of 11-50 employees is led by co-founder and CEO Jen Keane, a former Nike and adidas designer, and co-founder and CTO Dr. Ben Reeve, a bioengineering PhD. Recent operating moves include Butterfly Mark sustainability certification in 2025 and the build-out of operations and growth leadership in preparation for scaled manufacturing.

Short descriptiontext

Modern Synthesis is a London-based biomaterials company founded in 2020 that produces bacterial nanocellulose materials grown from engineered bacteria, supplying fashion, footwear, and automotive brands as a lower-impact alternative to leather and synthetics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bacterial nanocellulose materials, bio-based coated textiles, microbial fermentation platforms, sustainable leather alternatives, biomaterials for fashion
Industry3 codes
PRIMARYIMAMALAD
Nanocellulose & Cellulose Derivatives (CNC/CNF, MCC, ethers/esters)
SECONDARYEUAAAIAD
Bio-based Materials & Fibers (e.g., cellulose derivatives, lignin-based materials, nanocellulose)
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
SECONDARYIMAMALAK
Bio-based Textiles & Fibers (lyocell/viscose, cellulose filament, nonwovens)
NAICS code2 codes
  • Artificial and Synthetic Fibers and Filaments Manufacturing32522
  • Fiber, Yarn, and Thread Mills31311
SIC code2 codes
  • Leather & Leather Products3100
  • Apparel & Other Finishd Prods Of Fabrics & Similar Matl2300
Product category
Bio-based Textiles
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Bio-based Material Sales
TypeHardware Sales
Description

Modern Synthesis sells its bacterial nanocellulose-based materials to fashion and automotive brands as a material supplier. The company positions itself as a premium material provider for brands seeking sustainable alternatives to animal leather and petrochemical-derived textiles. Revenue is generated through material sales and potentially licensing of technology.

tech.eu
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Modern Synthesis develops bacterial nanocellulose materials grown via microbial fermentation using the Komagataeibacter rhaeticus bacterium, then bio-coats those nanocellulose sheets onto textile substrates to produce leather-alternative materials. The company sells its bio-based coated textiles directly to fashion, footwear, and apparel brands as biodegradable, lower-carbon replacements for traditional leather and petrochemical-derived fabrics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Carbon footprint is a fraction of that produced by animal and PU leather production
+1 more record
Product overview1 text field

Modern Synthesis is a biotechnology company that has developed a proprietary microbial textile platform for growing bacterial nanocellulose materials. The company's core offering consists of microbially-derived nanocellulose produced through fermentation of Komagataeibacter rhaeticus bacteria, which is processed into bio-based coated textiles designed as drop-in replacements for animal leather, synthetic leathers, and petrochemical-derived textiles. The platform technology connects biology (bacterial fermentation), material science (nanocellulose network formation), predictive intelligence (ML-driven optimization), and industry (manufacturing compatibility). Products include the signature bacterial nanocellulose materials and bio-based coated textiles for fashion, automotive, and other industries, with notable collaborations such as the GANNI Bou Bag (2023) and BEEN London Tote (2025). The company also participates in the Korvaa Consortium, combining their nanocellulose with mycelium and bio-based PHAs for concept footwear applications.

Product and service2 records
1Bacterial Nanocellulose Materials
CategoryBio-based Materials
Description

Bacterial nanocellulose sheets grown via microbial fermentation using the Komagataeibacter rhaeticus bacterium, serving as the foundational bio-based material input for downstream coated textile products. Designed for fashion, footwear, and apparel manufacturers seeking biodegradable, lower-carbon alternatives to animal leather and petrochemical-derived fabrics.

2Bio-based Coated Textiles
CategoryBio-based Textiles
Description

Bio-based coated textiles in which bacterial nanocellulose sheets are coated onto textile substrates, producing a leather-like material suitable for handbags, accessories, apparel, and footwear uppers. Sold to fashion and footwear brands as a biodegradable, lower-carbon alternative to leather and synthetics.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-06-01
Description

Korvaa Consortium partner contributing mycelium technology. The Korvaa shoe combines Modern Synthesis' bacterial nanocellulose, Ecovative's mycelium, and Ourobio's bio-based PHAs. Concept footwear unveiled at Future Fabrics Expo 2025.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-06-01
Description

Korvaa Consortium partner 3D printing soles using polyhydroxyalkanoates (PHAs). The Korvaa shoe combines three biomaterial technologies: bacterial nanocellulose (Modern Synthesis), mycelium (Ecovative), and bio-based PHAs (Ourobio).

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Circular design studio collaborated with Modern Synthesis on a Medium Tote bag made from bio-based coated textile, demonstrated in 2025.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-01
Description

Danish fashion brand collaborated with Modern Synthesis to create a handbag made from bacterial nanocellulose. The 'Bou Bag' was unveiled at London Design Festival 2023, showcasing viability of bacterial cellulose-based materials in real-world fashion applications. Plans to commercialize by early 2025 (though timeline was missed).

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

MycoWorks grows Fine Mycelium leather as a direct alternative to animal leather for fashion and automotive interiors. It is the most direct competitor to Modern Synthesis in the bio-based coated textile category, with deeper capital and a built-out commercial production facility.

TypeDirect peer
Description

Pioneer in bioengineered proteins and textile fibers (e.g., Microsilk, Mylo) used as leather and silk alternatives. Direct peer in the alternative-materials-for-fashion space, with a similar B2B co-development GTM and a much longer commercial history (and the prior capital intensity issues that Modern Synthesis's drop-in strategy explicitly tries to avoid).

TypeDirect peer
Description

Ecovative produces mycelium-based materials for packaging, textiles, and food. It is a direct peer in biomaterial leather alternatives and is also a named partner to Modern Synthesis in the Korvaa Consortium, making the comparison particularly relevant.

TypeDirect peer
Description

Spiber brews protein-based fibers (Brewed Protein) used as textile and leather alternatives. Comparable to Modern Synthesis in deploying fermentation-based bioprocesses to produce premium alternatives to animal and petrochemical materials for fashion brands.

TypeEmerging player
Description

Keel Labs produces seaweed-based fibers (Kelsun) as a sustainable alternative to cotton and synthetics. The overlap is partial - both target premium sustainable textiles with a bio-based feedstock, but the feedstock and process technology differ.

TypeEmerging player
Description

Natural Fiber Welding produces plant-protein-based materials (Mirum) for use as leather alternatives in fashion and automotive. Closely comparable in end-use to Modern Synthesis's bacterial nanocellulose, with a different feedstock and processing approach.

TypeEmerging player
Description

Balena produces bio-based, biodegradable thermoplastic materials (BioCir) for fashion and footwear. Adjacent in the bio-based coatings/materials space and a relevant peer for tracking second-generation biomaterials competitors.

TypeEmerging player
Description

Polybion produces bacterial cellulose (Celium) as a leather alternative. Closest peer to Modern Synthesis in terms of feedstock (bacterial cellulose) and process platform, and competes in the same fashion and luxury materials segment.

TypeBroad incumbent
Description

Lenzing is a large incumbent producer of cellulose-based fibers (lyocell, modal, viscose) used broadly in textiles and apparel. Sits in the broader bio-based cellulose fiber category and represents the established scale competitor that novel entrants like Modern Synthesis must compete against on cost and reliability.

TypeOthers
Description

Biofabricate is a consultancy, ecosystem organizer, and summit host in the biomaterials and fashion space. Not a direct competitor but a relevant ecosystem player that connects Modern Synthesis with brand partners and thought leadership visibility.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Modern Synthesis

Bio-based Textilesmodern-synthesis.com

Modern Synthesis is a London-based biomaterials company founded in 2020 that produces bacterial nanocellulose materials grown from engineered bacteria, supplying fashion, footwear, and automotive brands as a lower-impact alternative to leather and synthetics.

What Modern Synthesis does

Modern Synthesis is a London-based biomaterials company founded in 2020 that develops and supplies bacterial nanocellulose (BNC) materials grown from the Komagataeibacter rhaeticus bacterium. The company operates a proprietary, patent-pending BNC platform supported by an academic collaboration with Imperial College, and layers a machine-learning-driven material optimization workflow over the wet-lab process to accelerate iteration on properties such as hand-feel, strength, and dye uptake. The commercial proposition targets B2B customers in fashion and, increasingly, automotive interiors, where the material is positioned as a lower-impact, drop-in alternative to leather and synthetic substrates.

The company sells biomaterial sheets and finished prototypes to brand partners on a project and licensing basis rather than through disclosed high-volume contracts. Early commercial showcases include the 2023 GANNI Bou Bag and a BEEN London tote demonstration piece, with a 2025 Korvaa Consortium shoe marking entry into footwear. Revenue conversion has lagged announced timelines, and the company has publicly acknowledged difficulty achieving commercial sales, indicating that to date activity sits in the pilot-to-early-commercial phase supported by a brand waitlist rather than recurring volume.

Modern Synthesis is venture-backed, having raised approximately $4.1M in a June 2022 seed round and $5.5M in a February 2025 seed extension led by Extantia Capital, alongside Innovate UK non-dilutive funding. The team of 11-50 employees is led by co-founder and CEO Jen Keane, a former Nike and adidas designer, and co-founder and CTO Dr. Ben Reeve, a bioengineering PhD. Recent operating moves include Butterfly Mark sustainability certification in 2025 and the build-out of operations and growth leadership in preparation for scaled manufacturing.

Modern Synthesis firmographics

Firmographics
Name
Modern Synthesis
Legal name
Modern Synthesis
Website
https://modern-synthesis.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Modern Synthesis is a London-based biomaterials company founded in 2020 that produces bacterial nanocellulose materials grown from engineered bacteria, supplying fashion, footwear, and automotive brands as a lower-impact alternative to leather and synthetics.
Ownership category
akta.pro rank

Modern Synthesis industry classification

Industry
Product category
Bio-based Textiles
NAICS
Artificial and Synthetic Fibers and Filaments Manufacturing (32522), Fiber, Yarn, and Thread Mills (31311)
SIC
Leather & Leather Products (3100), Apparel & Other Finishd Prods Of Fabrics & Similar Matl (2300)
akta.pro industry
PRIMARYIMAMALAD
Nanocellulose & Cellulose Derivatives (CNC/CNF, MCC, ethers/esters)
SECONDARYEUAAAIAD
Bio-based Materials & Fibers (e.g., cellulose derivatives, lignin-based materials, nanocellulose)
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
SECONDARYIMAMALAK
Bio-based Textiles & Fibers (lyocell/viscose, cellulose filament, nonwovens)

Keywords

  • Bacterial nanocellulose materials
  • Bio-based coated textiles
  • Microbial fermentation platforms
  • Sustainable leather alternatives
  • Biomaterials for fashion

Where Modern Synthesis is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Modern Synthesis business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Bio-based Material Sales: Modern Synthesis sells its bacterial nanocellulose-based materials to fashion and automotive brands as a material supplier. The company positions itself as a premium material provider for brands seeking sustainable alternatives to animal leather and petrochemical-derived textiles. Revenue is generated through material sales and potentially licensing of technology.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Modern Synthesis product offering

Product offering

Core offering

Modern Synthesis develops bacterial nanocellulose materials grown via microbial fermentation using the Komagataeibacter rhaeticus bacterium, then bio-coats those nanocellulose sheets onto textile substrates to produce leather-alternative materials. The company sells its bio-based coated textiles directly to fashion, footwear, and apparel brands as biodegradable, lower-carbon replacements for traditional leather and petrochemical-derived fabrics.

Product overview

Modern Synthesis is a biotechnology company that has developed a proprietary microbial textile platform for growing bacterial nanocellulose materials. The company's core offering consists of microbially-derived nanocellulose produced through fermentation of Komagataeibacter rhaeticus bacteria, which is processed into bio-based coated textiles designed as drop-in replacements for animal leather, synthetic leathers, and petrochemical-derived textiles. The platform technology connects biology (bacterial fermentation), material science (nanocellulose network formation), predictive intelligence (ML-driven optimization), and industry (manufacturing compatibility). Products include the signature bacterial nanocellulose materials and bio-based coated textiles for fashion, automotive, and other industries, with notable collaborations such as the GANNI Bou Bag (2023) and BEEN London Tote (2025). The company also participates in the Korvaa Consortium, combining their nanocellulose with mycelium and bio-based PHAs for concept footwear applications.

Differentiator

Problem solved

Functional benefit

Products and services

  • Bacterial Nanocellulose Materials Bacterial nanocellulose sheets grown via microbial fermentation using the Komagataeibacter rhaeticus bacterium, serving as the foundational bio-based material input for downstream coated textile products. Designed for fashion, footwear, and apparel manufacturers seeking biodegradable, lower-carbon alternatives to animal leather and petrochemical-derived fabrics.
  • Bio-based Coated Textiles Bio-based coated textiles in which bacterial nanocellulose sheets are coated onto textile substrates, producing a leather-like material suitable for handbags, accessories, apparel, and footwear uppers. Sold to fashion and footwear brands as a biodegradable, lower-carbon alternative to leather and synthetics.

Quantifiable outcome

  • Carbon footprint is a fraction of that produced by animal and PU leather production
  • +1 more outcomes

Companies that use Modern Synthesis

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Modern Synthesis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Modern Synthesis partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • EcovativecoreTechnology or Integration · 1 June 2025Korvaa Consortium partner contributing mycelium technology. The Korvaa shoe combines Modern Synthesis' bacterial nanocellulose, Ecovative's mycelium, and Ourobio's bio-based PHAs. Concept footwear unveiled at Future Fabrics Expo 2025.
  • OurobiocoreTechnology or Integration · 1 June 2025Korvaa Consortium partner 3D printing soles using polyhydroxyalkanoates (PHAs). The Korvaa shoe combines three biomaterial technologies: bacterial nanocellulose (Modern Synthesis), mycelium (Ecovative), and bio-based PHAs (Ourobio).
  • BEEN LondonminorStrategic or Co-development Partner · 1 January 2025Circular design studio collaborated with Modern Synthesis on a Medium Tote bag made from bio-based coated textile, demonstrated in 2025.
  • GANNIcoreStrategic or Co-development Partner · 1 September 2023Danish fashion brand collaborated with Modern Synthesis to create a handbag made from bacterial nanocellulose. The 'Bou Bag' was unveiled at London Design Festival 2023, showcasing viability of bacterial cellulose-based materials in real-world fashion applications. Plans to commercialize by early 2025 (though timeline was missed).

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Modern Synthesis competitors and assessment

Company assessment

Direct peers

  • MycoWorks: MycoWorks grows Fine Mycelium leather as a direct alternative to animal leather for fashion and automotive interiors. It is the most direct competitor to Modern Synthesis in the bio-based coated textile category, with deeper capital and a built-out commercial production facility.
  • Bolt Threads: Pioneer in bioengineered proteins and textile fibers (e.g., Microsilk, Mylo) used as leather and silk alternatives. Direct peer in the alternative-materials-for-fashion space, with a similar B2B co-development GTM and a much longer commercial history (and the prior capital intensity issues that Modern Synthesis's drop-in strategy explicitly tries to avoid).
  • Ecovative: Ecovative produces mycelium-based materials for packaging, textiles, and food. It is a direct peer in biomaterial leather alternatives and is also a named partner to Modern Synthesis in the Korvaa Consortium, making the comparison particularly relevant.
  • Spiber: Spiber brews protein-based fibers (Brewed Protein) used as textile and leather alternatives. Comparable to Modern Synthesis in deploying fermentation-based bioprocesses to produce premium alternatives to animal and petrochemical materials for fashion brands.

Emerging players

  • Keel Labs: Keel Labs produces seaweed-based fibers (Kelsun) as a sustainable alternative to cotton and synthetics. The overlap is partial - both target premium sustainable textiles with a bio-based feedstock, but the feedstock and process technology differ.
  • Natural Fiber Welding: Natural Fiber Welding produces plant-protein-based materials (Mirum) for use as leather alternatives in fashion and automotive. Closely comparable in end-use to Modern Synthesis's bacterial nanocellulose, with a different feedstock and processing approach.
  • Balena: Balena produces bio-based, biodegradable thermoplastic materials (BioCir) for fashion and footwear. Adjacent in the bio-based coatings/materials space and a relevant peer for tracking second-generation biomaterials competitors.
  • Polybion: Polybion produces bacterial cellulose (Celium) as a leather alternative. Closest peer to Modern Synthesis in terms of feedstock (bacterial cellulose) and process platform, and competes in the same fashion and luxury materials segment.

Broad incumbents

  • Lenzing Group: Lenzing is a large incumbent producer of cellulose-based fibers (lyocell, modal, viscose) used broadly in textiles and apparel. Sits in the broader bio-based cellulose fiber category and represents the established scale competitor that novel entrants like Modern Synthesis must compete against on cost and reliability.

Others

  • Biofabricate: Biofabricate is a consultancy, ecosystem organizer, and summit host in the biomaterials and fashion space. Not a direct competitor but a relevant ecosystem player that connects Modern Synthesis with brand partners and thought leadership visibility.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Modern Synthesis social profiles

Digital presence

Modern Synthesis compliance and trust

Trust signal

Compliance1 record

Modern Synthesis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Modern Synthesis leadership team

Management profile

Number of profiles

Profiles5 records

Modern Synthesis funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Modern Synthesis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Modern Synthesis

What does Modern Synthesis do?

Modern Synthesis develops bacterial nanocellulose materials grown via microbial fermentation using the Komagataeibacter rhaeticus bacterium, then bio-coats those nanocellulose sheets onto textile substrates to produce leather-alternative materials. The company sells its bio-based coated textiles directly to fashion, footwear, and apparel brands as biodegradable, lower-carbon replacements for traditional leather and petrochemical-derived fabrics.

Is Modern Synthesis a public or private company?

Modern Synthesis is a private company. It is classified as venture growth investor backed and is currently operating.

When was Modern Synthesis founded?

Modern Synthesis was founded in 2020. It employs 11 to 50 people.

Where is Modern Synthesis based?

Modern Synthesis is headquartered in London, United Kingdom, in the Europe region.

How does Modern Synthesis make money?

One revenue line is on record: bio-based Material Sales.

Who are Modern Synthesis's main competitors?

Direct peers on record are MycoWorks, Bolt Threads, Ecovative and Spiber. Emerging players are Keel Labs, Natural Fiber Welding, Balena and Polybion. Lenzing Group is listed as a broad incumbent. Biofabricate is listed as an others.

Does Modern Synthesis have an API?

No public API is recorded for Modern Synthesis.

What industry is Modern Synthesis in?

Modern Synthesis's product category is Bio-based Textiles. Its primary akta.pro industry code is IMAMALAD, Nanocellulose & Cellulose Derivatives (CNC/CNF, MCC, ethers/esters), with a secondary code of EUAAAIAD, Bio-based Materials & Fibers (e.g., cellulose derivatives, lignin-based materials, nanocellulose). Its NAICS code is 32522 and its SIC code is 3100.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ThefashionglobeLab Grown Leather Fails to Attract Fashion BuyersBacterial leather startup Modern Synthesis, despite having functional technology, industry recognition, and £5.6 million in funding, has failed to achieve commercial sales six years after founding, with the only public product—a GANNI handbag prototype—missing its early 2025 launch date. The company's experience mirrors the broader collapse of biomaterial startups, including Bolt Threads which spent over £160 million before pausing production in 2023, highlighting a persistent gap between laboratory performance and commercial viability in sustainable materials. Modern Synthesis faces structural challenges including inconsistent waterproofing performance, insufficient production capacity to meet brand demand, and a funding runway that falls short of the decade typically required for material science commercialization.NetzeroinsightsFive Startups in Nanomaterials Transforming Industrial DecarbonizationThis article profiles five startups developing nanomaterials for industrial decarbonization: Lyten, Ionic Mineral Technologies, Keey Aerogel, Evove, and Modern Synthesis, each addressing emissions reduction through distinct material innovations. Lyten produces 3D Graphene for lithium-sulfur batteries and composites using a proprietary carbon-sequestration process, while Ionic Mineral Technologies supplies nano-silicon anode materials for batteries from halloysite clay deposits. Keey Aerogel manufactures low-carbon aerogel insulation from construction waste for electric vehicle battery safety, Evove provides graphene oxide-coated precision membranes for water recycling, and Modern Synthesis creates nanocellulose materials to replace plastics and animal leather. The featured companies collectively raised over $260 million in recent funding rounds to scale production and commercialization.MessefrankfurtAlternative leathers: Market trends & innovationsAlternative leather companies are expanding beyond fashion into automotive, hospitality, and furniture sectors to secure larger order volumes needed for production scale-up, as fashion alone presents challenges including longer development times and insufficient demand in early stages. The article profiles multiple companies including MycoWorks (mycelium-based Reishi with new Rei-Tanning technology), Modern Synthesis (bacterial nanocellulose via Korvaa Consortium), Revoltech (hemp-based LOVR and algae-based MATTR), Von Holzhausen (plant-based Liquidplant), Uncaged Innovations (plant-based ELEVATE), Beyond Leather (apple waste-based Leap), The Organoid Company and Lab-Grown Leather (cultivated T-Rex leather), HyphaLite, and 3DBT (lab-grown tissue-engineered skin). Notable partnerships include Revoltech's exclusive automotive development with Volkswagen, TAKT's furniture collaboration with Beyond Leather, and Mercedes-Benz work with Von Holzhausen.designboomkorvaa shoes come to life using mycelium, bacterial nanocellulose and biodegradable plasticsThe Korvaa Consortium unveiled concept footwear made from mycelium, bacterial nanocellulose, and biodegradable plastics at the Future Fabrics Expo 2025 in London on June 24–25. The shoe is a three-way biomaterial collaboration: Modern Synthesis supplied the bacterial nanocellulose upper, Ourobio 3D printed the sole using polyhydroxyalkanoates, and Ecovation grew mycelium in the sole over seven days. The concept footwear demonstrates how nature-based materials can replace traditional synthetic components, with a documentary titled "Planet of the Microbes" also documenting the production process.FinSMEsModern Synthesis Raises $5.5M in FundingModern Synthesis, a London-based biotechnology company, raised $5.5M in funding from Extantia Capital with participation from Artesian, Collab Fund, and others. The company will use the funds to expand operations and development efforts. It develops microbially-derived biomaterials as alternatives to animal leather and plastic-based textiles.Tech.euModern Synthesis secures $5.5M for bio-based alternatives to animal and plastic-based textilesModern Synthesis closed a $5.5 million funding round led by Extantia Capital to expand production of bio-based textiles. The company transforms nanocellulose into leather-like and plastic-free materials, aiming to address a projected 133 million tonne shortfall in low-impact raw materials by 2030.MediumBringing Life to Materials to Replace Plastics and Leather: Why We Invested in Modern SynthesisExtantia led a $5.5M funding round for Modern Synthesis, a London startup that transforms bacterial nanocellulose into leather and plastic alternatives. The company's roll-to-roll production aims to scale for fashion, footwear, and automotive, with a projected 100 Mt CO2e annual reduction by 2050.TechCrunchModern Synthesis is making compostable materials that last a lifetimeModern Synthesis, a startup led by Jen Keane, uses bacteria-grown nanocellulose to create biodegradable materials like artificial leather and films. The company closed a $5.5 million funding round led by Extantia Capital and is working to quintuple production at its pilot plant. It is exploring applications such as smart textiles and car dashboards.CnnSee how a bacteria isolated from kombucha is being used to make a new fabricStart-up Modern Synthesis is using bacteria to create sustainable materials, aiming to produce low-carbon alternatives to traditional fabrics. The bacteria can produce fibers eight times stronger than steel, and the company seeks to curb emissions and plastic pollution from the fashion industry.